AzTrials
AzTrials

Healthy SubjectsMETHODONCT02887053

Methodological Developments for Magnetic Resonance Imaging (MRI)

A study testing MRI in people with Healthy Subjects, run by Central Hospital, Nancy, France at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to optimize clinical MR protocols and to validate MR acquisition parameters. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Healthy Subjects
What is being tested?
MRI
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,807 participants
Where
1 siteFrance
Study dates
Nov 2008to 26 May 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • to be over 18 year-old,
  • to be able to give an informed consent,
  • to have underwent a pre-inclusion medical examination,
  • to present no contraindication to MR examination,
  • to be enrolled in a social security plan.

Who cannot join

  • subject refusal,
  • subject under a measure of legal protection,
  • any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ).

Trial locations and contacts

1 site in 1 country.

France1 site

  • CHRU de Nancy

    Nancy, 5400

Other trials in France

About this study

Official title: Développement Méthodologique de l'Imagerie Par Résonance Magnétique (IRM)

The purpose of this study is to optimize clinical MR protocols and to validate MR acquisition parameters.

Being tested
MRI
Keywords
MRI, Healthy subjects

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MRIDevice

Study groups in NCT02887053
Study groupRoleWhat they receive
All subjectsExperimentalAll subjects will have an MRI examination
Receives: Device: MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Image quality based on standard imaging quality criteria

    Image quality criteria will be :

    • Signal to Noise Ratio and Contrast to Noise Ratio measured in arbitrary units.
    • absence of blurring and artefacts will be assessed by at least one radiologist according to an ordinal scale

    Measured: 6 months after the last inclusion

Secondary outcomes (7)

  1. T1/T2 Quantitative sub studies

    For quantitative studies such as T1/T2 studies a T1/T2 quantification will be calculated. These parameters will be reported in ms.

    Measured: 6 months after the last inclusion

  2. Brain Functional MRI sub studies

    For functional MRI studies, brain activity will be described in terms of brain localisation based on blood oxygen level-dependent signal variation and its intensity.

    Measured: 6 months after the last inclusion

  3. Cardiac function MRI sub studies: volume

    For cardiac imaging, cardiac function will be evaluated. Parameters such as left ventricle (LV) and right ventricle (RV) end-diastolic volumes end-systolic volumes will be measured and reported in mL/m².

    Measured: 6 months after the last inclusion

  4. Cardiac mass MRI sub studies: mass

    For cardiac imaging, cardiac function will be evaluated. LV and RV mass index will be measured and reported in g/m2.

    Measured: 6 months after the last inclusion

  5. Cardiac function MRI sub studies: ejection fraction

    For cardiac imaging, cardiac function will be evaluated. Ejection fraction for both ventricles will be calculated and reported in %.

    Measured: 6 months after the last inclusion

  6. Diffusion weighted MRI sub studies

    For diffusion studies, the apparent diffusion coefficient (ADC) whic is a measure of the magnitude of diffusion (of water molecules) within tissue will be estimated (mm2/s).

    Measured: 6 months after the last inclusion

  7. Diffusion tensor MRI sub studies

    The fractional anisotropy (FA) which is a scalar value between zero and one, which describes the degree of anisotropy of a diffusion process, could also be estimated.

    Measured: 6 months after the last inclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2016 (estimated)
  2. Study startNov 2008
  3. Primary completion26 May 2022
  4. Study completion26 May 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
1,807 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02887053
Sponsor's protocol ID
2008-A01209-46
Acronym
METHODO
Status last verified
Mar 2026
First submitted
15 Jul 2016
Last updated
5 Mar 2026
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Isaieva K, Meullenet C, Vuissoz PA, Fauvel M, Nohava L, Laistler E, Zeroual MA, Henrot P, Felblinger J, Odille F. Feasibility of online non-rigid motion correction for high-resolution supine breast MRI. Magn Reson Med. 2023 Nov;90(5):2130-2143. doi: 10.1002/mrm.29768. Epub 2023 Jun 28.

    PubMed 37379467

  • Meullenet C, Isaieva K, Odille F, Dessale C, Felblinger J, Henrot P. Evaluation of Image Quality of Motion-Corrected Supine Breast MRI. Curr Probl Diagn Radiol. 2023 Nov-Dec;52(6):493-500. doi: 10.1067/j.cpradiol.2023.05.013. Epub 2023 May 11.

    PubMed 37258350

  • Isaieva K, Leclere J, Felblinger J, Gillet R, Dubernard X, Vuissoz PA. Methodology for quantitative evaluation of mandibular condyles motion symmetricity from real-time MRI in the axial plane. Magn Reson Imaging. 2023 Oct;102:115-125. doi: 10.1016/j.mri.2023.05.006. Epub 2023 May 13.

    PubMed 37187265

  • Douros IK, Xie Y, Dourou C, Isaieva K, Vuissoz PA, Felblinger J, Laprie Y. 3D Dynamic Spatiotemporal Atlas of the Vocal Tract during Consonant-Vowel Production from 2D Real Time MRI. J Imaging. 2022 Aug 25;8(9):227. doi: 10.3390/jimaging8090227.

    PubMed 36135393

  • Isaieva K, Fauvel M, Weber N, Vuissoz PA, Felblinger J, Oster J, Odille F. A hardware and software system for MRI applications requiring external device data. Magn Reson Med. 2022 Sep;88(3):1406-1418. doi: 10.1002/mrm.29280. Epub 2022 May 4.

    PubMed 35506503

  • Draveny R, Ambarki K, Han F, Hilbert T, Laurent V, Morel O, Bertholdt C, Beaumont M. Comparison of T2 Quantification Strategies in the Abdominal-Pelvic Region for Clinical Use. Invest Radiol. 2022 Jun 1;57(6):412-421. doi: 10.1097/RLI.0000000000000852. Epub 2022 Jan 10.

    PubMed 34999669

  • Le Bars AL, Moulin K, Ennis DB, Felblinger J, Chen B, Odille F. In Vivo Super-Resolution Cardiac Diffusion Tensor MRI: A Feasibility Study. Diagnostics (Basel). 2022 Mar 31;12(4):877. doi: 10.3390/diagnostics12040877.

    PubMed 35453925

  • Isaieva K, Laprie Y, Leclere J, Douros IK, Felblinger J, Vuissoz PA. Multimodal dataset of real-time 2D and static 3D MRI of healthy French speakers. Sci Data. 2021 Oct 1;8(1):258. doi: 10.1038/s41597-021-01041-3.

    PubMed 34599194

  • Soullie P, Missoffe A, Ambarki K, Felblinger J, Odille F. MR electrical properties imaging using a generalized image-based method. Magn Reson Med. 2021 Feb;85(2):762-776. doi: 10.1002/mrm.28458. Epub 2020 Aug 11.

    PubMed 32783236

  • Isaieva K, Laprie Y, Odille F, Douros IK, Felblinger J, Vuissoz PA. Measurement of Tongue Tip Velocity from Real-Time MRI and Phase-Contrast Cine-MRI in Consonant Production. J Imaging. 2020 May 13;6(5):31. doi: 10.3390/jimaging6050031.

    PubMed 34460733

  • Dos Reis JE, Odille F, Petitmangin G, Guillou A, Vuissoz PA, Felblinger J, Oster J. Broadband electrocardiogram acquisition for improved suppression of MRI gradient artifacts. Physiol Meas. 2020 May 7;41(4):045004. doi: 10.1088/1361-6579/ab7b8e.

    PubMed 32120353

  • Dos Reis JE, Soullie P, Oster J, Palmero Soler E, Petitmangin G, Felblinger J, Odille F. Reconstruction of the 12-lead ECG using a novel MR-compatible ECG sensor network. Magn Reson Med. 2019 Nov;82(5):1929-1945. doi: 10.1002/mrm.27854. Epub 2019 Jun 14.

    PubMed 31199011

  • Delbany M, Bustin A, Poujol J, Thomassin-Naggara I, Felblinger J, Vuissoz PA, Odille F. One-millimeter isotropic breast diffusion-weighted imaging: Evaluation of a superresolution strategy in terms of signal-to-noise ratio, sharpness and apparent diffusion coefficient. Magn Reson Med. 2019 Apr;81(4):2588-2599. doi: 10.1002/mrm.27591. Epub 2018 Dec 10.

    PubMed 30536764

  • Bustin A, Voilliot D, Menini A, Felblinger J, de Chillou C, Burschka D, Bonnemains L, Odille F. Isotropic Reconstruction of MR Images Using 3D Patch-Based Self-Similarity Learning. IEEE Trans Med Imaging. 2018 Aug;37(8):1932-1942. doi: 10.1109/TMI.2018.2807451. Epub 2018 Feb 19.

    PubMed 29994581

  • Dupont AC, Poussel M, Hossu G, Marie PY, Chenuel B, Felblinger J, Mandry D. Aortic compliance variation in long male distance triathletes: A new insight into the athlete's artery? J Sci Med Sport. 2017 Jun;20(6):539-542. doi: 10.1016/j.jsams.2016.10.009. Epub 2016 Oct 29.

    PubMed 27838232

Questions about this trial

What is this clinical trial studying?

A study testing MRI in people with Healthy Subjects, run by Central Hospital, Nancy, France at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Image quality based on standard imaging quality criteria (time frame: 6 months after the last inclusion). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02887053, which also lists 28 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in